More information coming soon. You can read the French version of this article.
Montreal, June 22, 2020. CQDM is pleased to announce an investment in Mesentech Inc., an emerging biotech based in Vancouver, British Columbia, developing a bone-targeting technology platform to deliver drugs selectively to bone-tissue. The lead program, MES-1007, aims to restore bone density and strength in conditions such as osteogenesis imperfecta (brittle bone disease), congenital muscular dystrophies (including Duchenne), renal osteodystrophy … Read More
Open letter – Published in the Hill Times (Ottawa) June 29th 2020 (https://www.hilltimes.com/2020/06/29/health-innovation-investing-now-to-face-the-crises-of-tomorrow/254763) & Published on LaPresse website June 20th 2020 (https://www.lapresse.ca/debats/opinions/2020-06-20/innovation-en-sante-investissons-maintenant-pour-faire-face-aux-crises-de-demain) Health innovation will play a key part in the battle against the devastating effects of the COVID-19 pandemic. As we have been doing since the beginning of the crisis, the leaders of the innovation ecosystem that includes our … Read More
Montreal, June 18, 2020 – The Canadian Cancer Society (CCS) and the Quebec Breast Cancer Foundation (QBCF), two leading organizations in funding breast cancer research, together with the biopharmaceutical research consortium CQDM, are proud to support the research conducted by Professor Yves St-Pierre at INRS-Institut Armand-Frappier. Valued at $1.15M, the project will support the development of next-generation immunotherapies against triple-negative … Read More
Montreal, June 18, 2020 – CQDM partners with the Canadian Cancer Society (CCS), the Quebec Breast Cancer Foundation (QBCF), the Armand-Frappier Foundation, the Canadian Glycomics Network (GlycoNet), Zymeworks and Pfizer as part of a $1.15M funding agreement. These funds will enable Professor Yves St-Pierre and his colleagues, Professors David Chatenet and Nicolas Doucet, to advance their work on breast cancer … Read More
June 16th 2020 – The Government of Quebec is launching the second call for proposals under the Fonds d’accélération des collaborations en santé (FACS). Consortia of partners from the public, private and non-profit sectors are invited to submit structuring projects that meet the current and future practical needs of companies in the life sciences sector. Proposed initiatives may involve any … Read More
19 mai 2020 – Ces moments difficiles mettent notre société au défi et nous obligent à être à la hauteur du rendez-vous que l’avenir nous donne. Dans le journal Le Monde, l’historien Yuval Noah Harari a récemment écrit que « Le véritable antidote à l’épidémie n’est pas le repli, mais la coopération » et ajoute « la véritable protection vient du … Read More
May 15th – 2020 – CQDM congratulates Theratechnologies and UQAM’s Professor Borhane Annabi for the positive results presented at the Virtual Annual Meeting II of the American Association for Cancer Research (AACR), particularly those obtained with its docetaxel-peptide conjugate TH-1902 for the treatment of triple-negative breast cancer. These are very encouraging results! To read Theratechnologies press release, click here.
Quebec City, Quebec, May 5th, 2020 – The biopharmaceutical research consortium CQDM and Medicago R&D are proud to announce today the funding of a research project that will allow the Quebec City-based company to increase the competitiveness of its vaccine production platform and confirm its position as leader in the biopharmaceutical industry in Canada. Through CQDM, the Ministry of Economy and … Read More
Fonds d’accélération des collaborations en santé (Health Collaboration Acceleration Fund) May 27th 2020 – To stimulate economic recovery in the life sciences sector, the Government of Quebec is making changes to the Fonds d’accélération des collaborations en santé (FACS) and inviting actors of the ecosystem to collaborate by launching ambitious projects that meet the practical needs of Quebec’s small and medium-sized … Read More
- Page 1 of 2